Novartis Sneaks Ahead Of Sanofi To Buy Gyroscope
Pays $800m Upfront For Gene Therapy Eye Specialist
Executive Summary
The Swiss giant is paying up to $1.5bn upfront to get hold of Gyroscope's AAV2-based one-time investigational gene therapy for geographic atrophy, an advanced form of dry AMD that leads to irreversible vision loss.
You may also be interested in...
Novartis Eyes Leaner Ophthalmic Business In Xiidra Deal With Bausch + Lomb
The Swiss drug maker said it would sell the underperforming dry eye drug plus pipeline assets and rights to a delivery device for $2.5bn, which for Bausch + Lomb means a bigger presence in the space.
The Eyes Still Have It For Novartis Despite Sell-Off Rumors
Rumors have resurfaced that Novartis is looking to shift some of its eye drugs but the Basle-based behemoth tells Scrip it remains committed to in-market products and R&D projects in the ophthalmology space.
Gilead Grabs MiroBio's Checkpoint Agonists For $405m
Just over a month after raising $97m in a series B round, Oxford University spinout MiroBio and its immune checkpoint agonists have been snapped up by Gilead Sciences.